Author:
Cutter Gary,Veneziano Antonella,Grinspan Augusto,Al-Banna Mahir,Boyko Alexey,Zakharova Maria,Maida Eva,Pasic Marija Bosnjak,Gandhi Sanjay K.,Everts Robin,Cordioli Cinzia,Rossi Silvia
Subject
Clinical Neurology,Neurology,General Medicine
Reference24 articles.
1. Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis;Achiron;Mult. Scler.,2003
2. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease;Atkinson;Health Qual. Life Outcomes,2004
3. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
4. Relapses and progression of disability in multiple sclerosis;Confavreux;N. Engl. J. Med.,2000
5. Copaxone® (glatiramer acetate) [prescribing information]. Overland Park, KS: Teva Neuroscience, Inc.; January 2018.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献